{"title":"Assessment of programmed death ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and carcinoma cervix","authors":"Divya Shelly , Pragya Sharma , P.S. Mishra , Deepak Mulajker , Niharika Bisht , Hari Mukundan , Shiv Kumar","doi":"10.1016/j.mjafi.2024.02.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><span>Carcinoma cervix<span><span> is a significant public health issue in low- and middle-income nations. Despite the availability of aggressive cytological screening tests and increasing accessibility of the </span>Human Papilloma Virus vaccine<span><span>, a significant proportion of patients in our country still present with locally advanced cervical cancer. The objective of this study was to estimate the prevalence of </span>programmed death ligand 1 (PD-L1) immunoexpression in </span></span></span>cervical intraepithelial neoplasia and carcinoma cervix and study the distribution of clinicopathological features and recurrence of cervical cancer with respect to PD-L1 status.</div></div><div><h3>Methods</h3><div>A total of 140 patients were included in this multicentric ambidirectional study. Immunohistochemical analysis for PD-L1 was performed on paraffin-embedded, formalin-fixed sections using 22C3 PharmDx assay (Dako) and tumour proportion score was calculated. PD-L1 expression status concerning the distribution of clinicopathological features was further studied.</div></div><div><h3>Results</h3><div><span>This study included 133 cases of cervical carcinoma and 7 cases of cervical intraepithelial neoplasia (140 cases), with a prevalence of PDL1 positivity in 31.4% of cases with 15% (n = 21) tumours high positive, 16.4% (n = 23) low positive and 68.6% (n = 96) negative for PD-L1. It was observed that all cases with PD-L1 positivity were characterized as </span>squamous cell carcinoma. The mean age of subjects was 56.74 ± 11.52 years. PD-L1 high positivity was observed in 26.7% of individuals in the age group >70 years, 21.7% of grade 3 tumours, 11.4% of tumours exceeding 4 cm in size, and 33.3% of cases showing recurrence. PD-L1 immunoexpression did not demonstrate a significant association with the patient's age, tumour grade and stage, as well as recurrence.</div></div><div><h3>Conclusion</h3><div><span>It is envisaged that anti-PD-L1 immunotherapy could show promising </span>antitumour activity<span> and early survival rates among patients with cervical squamous cell carcinoma.</span></div></div>","PeriodicalId":39387,"journal":{"name":"Medical Journal Armed Forces India","volume":"81 ","pages":"Pages S11-S16"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal Armed Forces India","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0377123724000340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Carcinoma cervix is a significant public health issue in low- and middle-income nations. Despite the availability of aggressive cytological screening tests and increasing accessibility of the Human Papilloma Virus vaccine, a significant proportion of patients in our country still present with locally advanced cervical cancer. The objective of this study was to estimate the prevalence of programmed death ligand 1 (PD-L1) immunoexpression in cervical intraepithelial neoplasia and carcinoma cervix and study the distribution of clinicopathological features and recurrence of cervical cancer with respect to PD-L1 status.
Methods
A total of 140 patients were included in this multicentric ambidirectional study. Immunohistochemical analysis for PD-L1 was performed on paraffin-embedded, formalin-fixed sections using 22C3 PharmDx assay (Dako) and tumour proportion score was calculated. PD-L1 expression status concerning the distribution of clinicopathological features was further studied.
Results
This study included 133 cases of cervical carcinoma and 7 cases of cervical intraepithelial neoplasia (140 cases), with a prevalence of PDL1 positivity in 31.4% of cases with 15% (n = 21) tumours high positive, 16.4% (n = 23) low positive and 68.6% (n = 96) negative for PD-L1. It was observed that all cases with PD-L1 positivity were characterized as squamous cell carcinoma. The mean age of subjects was 56.74 ± 11.52 years. PD-L1 high positivity was observed in 26.7% of individuals in the age group >70 years, 21.7% of grade 3 tumours, 11.4% of tumours exceeding 4 cm in size, and 33.3% of cases showing recurrence. PD-L1 immunoexpression did not demonstrate a significant association with the patient's age, tumour grade and stage, as well as recurrence.
Conclusion
It is envisaged that anti-PD-L1 immunotherapy could show promising antitumour activity and early survival rates among patients with cervical squamous cell carcinoma.
期刊介绍：
This journal was conceived in 1945 as the Journal of Indian Army Medical Corps. Col DR Thapar was the first Editor who published it on behalf of Lt. Gen Gordon Wilson, the then Director of Medical Services in India. Over the years the journal has achieved various milestones. Presently it is published in Vancouver style, printed on offset, and has a distribution exceeding 5000 per issue. It is published in January, April, July and October each year.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
